Department of Level: IV 72 males and 114 females Exclusion: Insertion: transnasally or transorally Chest pain Surgery and Quality: Q1 Mean age: 51 years Not stated Placement: 5– 6 cm above the LOS or Division of cm above the SCJ CX (no Indications: Gastroenterology, comparator) Duration: 48 hours Oregon Health Being evaluated for GORD and Science P2 Comparator: University, 24-hour Bravo monitoring Portland, Oregon, USA Mucosal abrasion Tu et al. () Prospective case 30 patients Inclusion: Index test: and minor series Department of 20 males, 10 females Not stated System: Bravo™ wireless capsule system haemorrhage Internal Medicine Mean age: 57.6 ± 14.3 years (range Exclusion: Insertion: transorally and Department Level: IV 29–83) Not stated Placement: 6 cm proximal to the GOJ of Emergency Quality: Q1 Indications: Medicine, Duration: 48 hours National Taiwan CX (no 24 patients with GORD were Comparator: NA University comparator) evaluated for drug effectiveness Hospital, Taipei, before surgery, 6 patients showed P2 Taiwan typical heartburn but their endoscopic findings were normal. Chest pain requiring Turner et al. () Case series 198 pH studies (148 studies had Inclusion: Index test: capsule removal enough data to be included) Division of Not stated System: Bravo™ wireless capsule system Gastroenterology, Off medical therapy: 115 patients, 76 Level: IV Exclusion: Insertion: (during endoscopy) Brigham and females, 39 males; mean age: 50 ± Quality: Q2 Not stated Placement: 6 cm above the SCJ Women’s 13 years Hospital, Boston, CX (no Duration: 48 hours On medical therapy: 33 patients, 26 Massachusetts, comparator) females, 7 males; mean age: 52 ± Comparator: NA USA 14 years P2 Indications: Typical and atypical symptoms of GORD or persistent GORD-related symptoms despite medical therapy. Patients with planned anti-reflux
Department of Surgery and Division of Gastroenterology, Oregon Health and Science University, Portland, Oregon, USA Level: IV Quality: Q1 CX (no comparator) P2 72 males and 114 females Mean age: 51 years Indications: Being evaluated for GORD Exclusion: Not stated Insertion: transnasally or transorally Placement: 5– 6 cm above the LOS or cm above the SCJ Duration: 48 hours Comparator: 24-hour Bravo monitoring Chest pain Tu et al. () Department of Internal Medicine and Department of Emergency Medicine, National Taiwan University Hospital, Taipei, Taiwan Prospective case series Level: IV Quality: Q1 CX (no comparator) P2 30 patients 20 males, 10 females Mean age: 57.6 ± 14.3 years (range 29–83) Indications: 24 patients with GORD were evaluated for drug effectiveness before surgery, 6 patients showed typical heartburn but their endoscopic findings were normal. Inclusion: Not stated Exclusion: Not stated Index test: System: Bravo™ wireless capsule system Insertion: transorally Placement: 6 cm proximal to the GOJ Duration: 48 hours Comparator: NA Mucosal abrasion and minor haemorrhage Turner et al. () Division of Gastroenterology, Brigham and Women’s Hospital, Boston, Massachusetts, USA Case series Level: IV Quality: Q2 CX (no comparator) P2 198 pH studies (148 studies had enough data to be included) Off medical therapy: 115 patients, 76 females, 39 males; mean age: 50 ± 13 years On medical therapy: 33 patients, 26 females, 7 males; mean age: 52 ± 14 years Indications: Typical and atypical symptoms of GORD or persistent GORD-related symptoms despite medical therapy. Patients with planned anti-reflux Inclusion: Not stated Exclusion: Not stated Index test: System: Bravo™ wireless capsule system Insertion: (during endoscopy) Placement: 6 cm above the SCJ Duration: 48 hours Comparator: NA Chest pain requiring capsule removal
1203-ContractedAssessmentReport-Catheter-free%20ambulatory%20pH%20test%20for%20GORD%20accessible.docx